Evidence map›Paper›PMID 42208702›Full record

Trial reportMagnetic resonance imaging2026

Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial.

Ricarda von Krüchten, Natalie J DelRocco, Lisa C Adams, Shashi Bhushan Singh, Zahra Shokri Varniab, Julia Glade Bender, Mark D Krailo, Steven DuBois, Heike E Daldrup-Link

Abstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Magnetic resonance imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ricarda von KrüchtenDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, 300 Pasteur Dr, Palo Alto, CA 94304, USA.
Natalie J DelRoccoDepartment of Population and Public Health Sciences, Division of Biostatistics, University of Southern California, 1845 N Soto St, Los Angeles, CA 90032, USA.
Lisa C AdamsDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, 300 Pasteur Dr, Palo Alto, CA 94304, USA.
Shashi Bhushan SinghDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, 300 Pasteur Dr, Palo Alto, CA 94304, USA.
Zahra Shokri VarniabDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, 300 Pasteur Dr, Palo Alto, CA 94304, USA.
Julia Glade BenderDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Mark D KrailoDepartment of Population and Public Health Sciences, Division of Biostatistics, University of Southern California, 1845 N Soto St, Los Angeles, CA 90032, USA.
Steven DuBoisDana-Farber / Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts; Department of Pediatrics, Harvard Medical School, 450 Brookline Ave, Boston, MA 02115, USA.
Heike E Daldrup-LinkDepartment of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, 300 Pasteur Dr, Palo Alto, CA 94304, USA. Electronic address: heiked@stanford.edu.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Advanced Imaging Tools to Assess Cancer Therapeutics in Pediatric PatientsR01CA269231 · NCI · STANFORD UNIVERSITY · PI Heike Elizabeth Daldrup-Link · 2022 to 2026
$3.5M
NCI NIH HHS R01 CA269231NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196173
6 · The paper itself

Abstract

RATIONALE AND

objectivesTo correlate quantitative measures of tumor cell density, derived from diffusion-weighted magnetic resonance imaging (MRI), with quantitative measures of tumor glucose metabolism, derived from 18F-FDG positron emission tomography (PET), and post-induction event-free survival (EFS) in patients with metastatic Ewing sarcoma. MATERIALS AND

methodsWe performed a secondary review of 21 patients (mean age 14.1 years ±4.67, 12 females) with metastatic Ewing sarcoma who were enrolled in a prospective, multicenter phase III clinical trial by the Children's Oncology Group (AEWS1221) and underwent paired diffusion-weighted MRI and

resultsBaseline ADC

conclusionBaseline ADC

Indexed as

Bone NeoplasmsDiffusion Magnetic Resonance ImagingSarcoma, EwingAdolescentChildFemaleFluorodeoxyglucose F18HumansMalePositron-Emission TomographyProspective StudiesRadiopharmaceuticalsTreatment OutcomeFluorodeoxyglucose F18RadiopharmaceuticalsApparent diffusion coefficientDiffusion-weighted MRIEwing sarcomaPositron emission tomographyTreatment response assessment

Identifiers

PMID42208702
PMCPMC13693368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.